Nakai 2000.

Methods	Randomised clinical trial.
Participants	Country: Japan. Number randomised: 23. Post‐randomisation dropouts: not stated. Revised sample size: 23. Mean age: 57 years. Females: not stated. Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): all participants followed up for 12 months. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: UDCA (low) + bezafibrate (n = 13). Further details: UDCA: 600 mg/day; duration: not stated + bezafibrate: 400 mg/day; duration: not stated. Group 2: UDCA (low) (n = 10). Further details: UDCA: 600 mg/day; duration: not stated.
Outcomes	None of the outcomes of interest reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: information not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: information not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	High risk	Comment: neither mortality nor adverse events reported.
For‐profit bias	Low risk	Quote: "This work was supported by a Grant‐in‐Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan".
Other bias	Low risk	Comment: no other source of bias.